1788873-48-2

Usage

Uses

Used in Pharmaceutical Research and Development:
(2,2-difluorohexahydro-1H-pyrrolizin-7a-yl)methanol is used as a research compound for the development of new drugs due to its unique structural features and potential pharmacological benefits. The presence of fluorine atoms is expected to contribute to the compound's improved metabolic stability, bioavailability, and target selectivity, which are crucial for drug efficacy and safety.
Used in Antiviral Drug Development:
In the antiviral industry, (2,2-difluorohexahydro-1H-pyrrolizin-7a-yl)methanol is used as a potential drug candidate for the development of antiviral treatments. Its unique structure and fluorine substitution may offer advantages in targeting viral processes and improving the effectiveness of antiviral therapies.
Used in Antibacterial Drug Development:
Within the antibacterial sector, (2,2-difluorohexahydro-1H-pyrrolizin-7a-yl)methanol is employed as a candidate for the creation of new antibacterial agents. (2,2-difluorohexahydro-1H-pyrrolizin-7a-yl)methanol's properties may contribute to overcoming bacterial resistance and providing more effective treatment options for various infections.
Used in Anti-inflammatory Drug Development:
In the field of anti-inflammatory drug development, (2,2-difluorohexahydro-1H-pyrrolizin-7a-yl)methanol is utilized as a potential therapeutic agent. Its structural and pharmacological attributes may aid in the management of inflammation and the treatment of related conditions, offering new avenues for therapeutic intervention.

Upstream product

• 942603-58-9 ethyl 2,5-dioxotetrahydro-1H-pyrrolizine-7a(5H)-carboxylate 
• 942603-91-0 ethyl 2-methylene-5-oxotetrahydro-1H-pyrrolizine-7a(5H)-carboxylate 
• 868066-08-4 ethyl 5-oxo-2-(2-chloromethylprop-2-enyl)pyrrolidine-2-carboxylate 
• 66183-71-9 ethyl 2-oxopyrrolidine-5-carboxylate 
• 251924-83-1 1-tert-butyl 2-ethyl 5-oxopyrrolidine-1,2-dicarboxylate 

Downstream Products

• 1788873-50-6 (2,2-difluorohexahydro-1H-pyrrolizin-7a-yl)methanamine 

Relevant academic research and scientific papers

Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice

The voltage-gated sodium channel Nav1.7 is a genetically validated target for the treatment of pain with gain-of-function mutations in man eliciting a variety of painful disorders and loss-of-function mutations affording insensitivity to pain.

QUINAZOLINE COMPOUNDS, PREPARATION METHODS AND USES THEREOF

Provided herein are novel compounds, for example, compounds having a Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof. Also provided herein are methods of preparing the compounds and methods of using the compounds, for example, in inhibiting KRAS G12D in a cancer cell, and/or in treating various cancer such as pancreatic cancer, colorectal cancer, lung cancer or endometrial cancer.

BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS

Disclosed are compounds of Formula (A-a), or a salt thereof, Where "B1" and "R1" through "R5" are as defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula (A-a) or their salts, and methods of treating neuropathic pain disorders using the same.

BICYCLOAMINE-SUBSTITUTED-N-BENZENESULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS

Disclosed are compounds of Formula A-a, or a salt thereof: Where "B1" and "R1" through "R5" are as defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formula A-a or their salts, and methods of treating neuropathic pain disorders using the same.